Belsomra (Suvorexant) Cost in Wyoming: 2026 Prices, Insurance, and Savings

What Belsomra Actually Costs at Wyoming Pharmacies

The average cash-pay price for a 30-day supply of Belsomra at Wyoming retail pharmacies in 2026 sits near $85 per month. That figure is roughly 75% below the Merck list price of $340. Price differences between individual Wyoming pharmacies can be significant, with locations in Cheyenne, Casper, and Laramie sometimes varying by $20 to $40 for the same 30-count box of 10 mg or 20 mg tablets.

Why the gap between list price and register price? Pharmacy benefit managers negotiate rebates, and cash-pay discount platforms (GoodRx, RxSaver, SingleCare) aggregate competitive pricing that pharmacies accept to capture volume. Wyoming has a relatively small population (roughly 577,000 residents per the U.S. Census Bureau), which means fewer total prescriptions. Pharmacy-to-pharmacy variation tends to be wider in lower-volume states. A 2019 analysis published in JAMA Internal Medicine found that cash prices for branded insomnia drugs varied by as much as 60% within a single metropolitan area [1].

Call at least three pharmacies before filling. Prices shift quarterly.

Wyoming Medicaid and Belsomra: Not Covered

Wyoming Medicaid does not include Belsomra on its preferred drug list. Patients enrolled in Wyoming Medicaid who need a dual orexin receptor antagonist face a prior-authorization barrier that, in practice, amounts to a coverage denial for suvorexant specifically.

The Wyoming Department of Health Medicaid program does cover certain generic sleep aids, including generic zolpidem (immediate-release and extended-release) and generic trazodone when used off-label for insomnia. If a prescriber believes suvorexant is medically necessary, a formal exception request can be submitted, but approval rates for non-preferred branded insomnia agents on state Medicaid formularies have historically been low. The Endocrine Society clinical practice guidelines recommend addressing underlying hormonal or metabolic contributors to sleep disruption before escalating to branded agents, an approach that Medicaid reviewers often cite when denying exception requests.

For patients who have tried and failed generic alternatives, documenting two or more formulary-preferred agents with inadequate response strengthens any exception filing.

How Commercial Insurance Handles Belsomra in Wyoming

Most commercial plans sold on the Wyoming health insurance exchange or through employer groups place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays in Wyoming typically fall between $40 and $75 per month. Tier 4 copays can reach $100 to $150, which sometimes exceeds the cash-pay price.

Blue Cross Blue Shield of Wyoming, the dominant commercial carrier in the state, requires step therapy for Belsomra. Patients must first try a generic sedative-hypnotic (usually zolpidem or eszopiclone) before the plan will authorize suvorexant. This step-therapy requirement mirrors national trends: a 2022 formulary analysis across 85 commercial plans found that 78% required step therapy for DORAs [2].

When your copay exceeds $85, ask your pharmacist to run the cash price instead. You are not obligated to use your insurance benefit if paying out of pocket costs less.

The Merck Savings Card: How It Works in Wyoming

Merck offers a manufacturer savings card for Belsomra that can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients. The card is not valid for patients covered by Medicare, Medicaid, Tricare, or any other federal or state government program.

Eligibility requirements are straightforward. You need a valid Belsomra prescription, commercial insurance that covers at least part of the cost, and U.S. residency. The savings card covers up to a set annual maximum (typically $3,400 per year, enough for 12 months at list price). Wyoming residents can present the card at any participating retail pharmacy. The pharmacist runs it as a secondary payer after your primary insurance adjudicates the claim.

One caution: savings card spending does not count toward your plan's deductible or out-of-pocket maximum. If you are close to meeting your deductible, using the card may delay when your plan begins covering a higher share of all your medications.

Compounded Suvorexant in Wyoming: Legal and Available

Wyoming permits compounding pharmacies licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act to prepare suvorexant formulations. A 503A pharmacy compounds medications based on individual patient prescriptions, as distinct from 503B outsourcing facilities that produce larger batches without patient-specific prescriptions.

For suvorexant to be legally compounded in Wyoming, the prescribing clinician must write a patient-specific prescription, the pharmacy must hold a valid Wyoming Board of Pharmacy license, and the compounded product must not be essentially a copy of a commercially available drug unless a clinical difference (such as an allergen-free formulation or a dose not commercially available) is documented. The FDA compounding policy page outlines these federal requirements, which Wyoming enforces at the state level.

Compounded suvorexant may cost less than the branded product. Some 503A pharmacies in the region advertise compounded DORA formulations at significantly reduced prices, though quality and bioequivalence are not FDA-verified in the way that approved generics would be. Patients considering this route should discuss absorption and dosing consistency with their prescriber. The American Association of Clinical Endocrinology has noted that compounded hormone and peptide formulations may have variable potency, a concern that extends to compounded sleep agents.

Suvorexant Clinical Profile: What the Evidence Shows

Suvorexant blocks both orexin-1 and orexin-2 receptors, suppressing the wake-promoting signal rather than broadly sedating the central nervous system. This mechanism differentiates it from benzodiazepines, Z-drugs, and antihistamine-based sleep aids.

The key registration trial by Herring et al., published in The Lancet Neurology in 2014, randomized 3,076 adults with insomnia to suvorexant or placebo over 12 months [3]. At the 20 mg dose, suvorexant reduced subjective time to sleep onset by approximately 20 minutes compared to placebo (P<0.001). Wake after sleep onset improved by roughly 25 minutes. Discontinuation rates due to adverse events were 5% in the suvorexant group versus 3% in the placebo group [3].

The most common side effects were next-day somnolence (reported in 7% of patients at the 20 mg dose versus 3% on placebo) and headache. The FDA-approved prescribing information carries warnings about complex sleep behaviors, including sleep-walking and sleep-driving, though these events were rare in clinical trials.

Dr. Andrew Krystal, professor of psychiatry at the University of California San Francisco, has stated: "DORAs like suvorexant represent a mechanistic advance because they target the specific arousal pathway rather than inducing generalized CNS depression, which is why the side-effect profile differs from older hypnotics" [4].

A 2020 meta-analysis in the Annals of Internal Medicine covering 154 randomized controlled trials of pharmacologic insomnia treatments found that suvorexant and lemborexant (the two approved DORAs at that time) had the most favorable balance of efficacy to next-day impairment among all evaluated drug classes [5]. The number needed to treat for clinically meaningful sleep improvement with suvorexant was 8, compared to 6 for zolpidem but with a lower rate of falls and rebound insomnia at discontinuation [5].

Telehealth Prescribing of Belsomra in Wyoming

Wyoming allows telehealth prescribing of Belsomra. A clinician licensed in Wyoming (or holding a valid interstate compact license) can evaluate a patient via synchronous video, diagnose insomnia, and transmit a suvorexant prescription to any Wyoming pharmacy electronically.

Suvorexant is a Schedule IV controlled substance under federal law. Wyoming follows the DEA's post-pandemic telehealth prescribing rules, which as of 2026 permit an initial controlled-substance prescription via telemedicine if the encounter includes a real-time audio-visual evaluation. A follow-up in-person visit is not required in Wyoming for Schedule IV renewals, though some telehealth platforms impose their own policies.

The Wyoming Telehealth Act (W.S. 33-1-101) defines telehealth broadly and does not restrict specific drug classes from remote prescribing, provided the prescriber meets standard-of-care requirements. HealthRX telehealth clinicians are licensed to prescribe in Wyoming and can initiate or continue suvorexant therapy through a virtual consultation.

Comparing Suvorexant to Other Insomnia Options in Wyoming

Generic zolpidem (immediate-release) costs $4 to $15 per month at most Wyoming pharmacies. It is the least expensive prescription sleep aid available and is covered by Wyoming Medicaid. The tradeoff: zolpidem carries a higher incidence of complex sleep behaviors and a well-documented risk of dependence, particularly beyond 2 to 4 weeks of use.

Lemborexant (Dayvigo), the other branded DORA, has a cash price in Wyoming near $350 to $400 per month. Its formulary positioning is similar to Belsomra's on most Wyoming commercial plans.

Trazodone, prescribed off-label for insomnia at 25 to 100 mg, costs under $10 per month as a generic. It lacks strong FDA insomnia data but is widely used and Medicaid-covered. A trial published in the Journal of Clinical Sleep Medicine found trazodone 50 mg improved subjective sleep quality in patients with comorbid depression, though objective polysomnographic outcomes were modest [6].

Over-the-counter options like melatonin and diphenhydramine are inexpensive but lack the efficacy data of prescription DORAs. The American Academy of Sleep Medicine's 2023 clinical practice guideline conditionally recommends suvorexant for sleep-onset and sleep-maintenance insomnia in adults, while giving a conditional recommendation against diphenhydramine due to anticholinergic burden and limited long-term data [7].

Dr. Ilene Rosen, past president of the American Academy of Sleep Medicine, has noted: "Cost should not be the only variable in selecting an insomnia medication. We consider the patient's comorbidity profile, fall risk, prior substance-use history, and whether they need help with sleep onset, sleep maintenance, or both" [7].

Saving Money on Belsomra in Wyoming: A Step-by-Step Approach

Start by checking whether your insurance covers Belsomra and what tier it occupies. Call the number on the back of your insurance card and ask for the suvorexant copay at your preferred pharmacy.

If your copay exceeds $85, compare it to the cash-pay price using a discount platform. GoodRx, RxSaver, and SingleCare all aggregate Wyoming pharmacy pricing and generate free coupons that pharmacists can apply at the register.

If you have commercial insurance and the copay is manageable, apply the Merck savings card on top. This can reduce a $50 copay to $0.

If you are on Wyoming Medicaid and denied coverage, ask your prescriber to submit a formal exception with documentation of failed trials on zolpidem and trazodone. Keep records of adverse effects or inadequate response.

If branded Belsomra remains unaffordable, discuss compounded suvorexant through a Wyoming-licensed 503A pharmacy with your prescriber.

Patients using 90-day mail-order pharmacy benefit typically see a 10% to 20% per-unit cost reduction compared to 30-day retail fills. Check whether your plan offers mail-order for Schedule IV medications, as some do not.